ELCC 2016: Targeting PD-1 and PD-L1 for lung cancer therapy

ELCC 2016: Targeting PD-1 and PD-L1 for lung cancer therapy

VJOncology

3 years
409 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Joseph Paul Eder, MD, from Yale University Cancer Center, New Haven, CT, explains the development of antibodies targeting the programmed death ligand 1 (PD-L1) and its receptor, programmed death 1 (PD-1) for the treatment of patients with non-small cell lung cancer (NSCLC), including clinical trials evaluating the integration of PD-1/PD-L1blocking antibodies with existing standard-of-care approaches.
Up Next Autoplay
Zomas Question 2
Zomas Question 2
Category: Chronic Myelogenous Leukemia
0 Views
admin 4 hours
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
Category: Chronic Lymphocytic Leukemia
3 Views
ash 6 hours
SWAY Study @LevineCancer #ASH19
SWAY Study @LevineCancer #ASH19
Category: Chronic Lymphocytic Leukemia
0 Views
ash 7 hours
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
admin 7 hours
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
ash 8 hours
Phase 2 CAPTIVATE Trial: What's Next? #ASH19 #ASH @PeterMacCC
Phase 2 CAPTIVATE Trial: What's Next? #ASH19 #ASH @PeterMacCC
Category: Chronic Lymphocytic Leukemia
0 Views
ash 9 hours
Phase 2 CAPTIVATE clinical trial in CLL #ASH19 #ASH @PeterMacCC
Phase 2 CAPTIVATE clinical trial in CLL #ASH19 #ASH @PeterMacCC
Category: Chronic Lymphocytic Leukemia
0 Views
ash 9 hours
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Category: Non-Hodgkin Lymphoma
4 Views
ash 22 hours
REGN5458 @RutgersCancer #ASH #ASH19
REGN5458 @RutgersCancer #ASH #ASH19
Category: Multiple Myeloma
6 Views
ash 23 hours
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Category: Multiple Myeloma
6 Views
ash 1 day